Eli Lilly Proves Its GLP-1 Dominance Again, Raising My Price Target [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
LLY's 2026 guidance calls for $80–83B revenue and $33.50–35 non-GAAP EPS, outpacing consensus and supporting a reiterated buy rating. Mounjaro and Zepbound drove $6.3B in incremental quarterly sales, cementing LLY's GLP-1 market dominance. A $1240–1300 price target is justified by premium margins, strong technicals, and a best-in-class growth outlook. JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) shares plunged this past Tuesday, following a disappointing Q4 earnings report and year-ahead outlook. Shares of the European-based GLP-1 weight-loss drugmaker fell further on the heels of strong numbers put out This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]MSNBC.com
- Novo Nordisk Q4: Slumping Due To Weak Guidance [Seeking Alpha]Seeking Alpha
- Novo to launch Ozempic pill for diabetes in second quarter of 2026 [BNN Bloomberg (Canada)]BNN Bloomberg
- Novo Nordisk: My Certainties Swept Away By A Quarterly Report (Downgrade) [Seeking Alpha]Seeking Alpha
- Eli Lilly: A Wonderful Company, But A Stock Priced For Perfection [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/4/26 - Form IRANNOTICE
- 2/4/26 - Form 20-F
- 2/4/26 - Form 6-K
- NVO's page on the SEC website